Metabolic Syndrome Components are Associated with Increased Prostate Cancer Risk

Our study investigated the associations of metabolic syndrome (MS) and metabolic indicators with prostate cancer (PCa) risk in the Chinese Han ethnic population.

We studied 101 PCa patients (without/with MS) and 120 healthy controls. Clinical data, including waist circumference, BMI, TG, FINS, FBG, and PCa-related indicators, were collected. The correlations between MS and PCa were analyzed.

Compared to PCa, PV and Gleason scores increased and PSA levels decreased in PCa with MS group (all P<0.001). PV was positively correlated with BMI, FINS, and HOMA-IR (r=0.459, P<0.001; r=0.421, P=0.001; r=0.490, P=0.003, respectively), and was negatively correlated with HDL-C (r=-0.378, P<0.001). PSA level in MS patients was negatively correlated with BMI (r=-0.125, P<0.001), TG (r=-0.256, P<0.001) and FBG (r=-0.183, P<0.001). Large PV, high TG, low HDL-C, high LDL-C, and high FBG were associated with an increased risk of PCa (P<0.001, OR=1.10, 95%CI: 1.009-3.304; P<0.001, OR=2.91, 95%CI: 1.612-5.241; P<0.001, OR=7.89, 95%CI: 3.908-15.947; P=0.015, OR=1.87, 95%CI: 1.131-3.077; P=0.004, OR=2.17, 95%CI: 1.280-3.686, respectively). MS-related indicators showed a positive relationship with PCa (P<0.001, OR=1.90, 95%CI: 1.107-10.629).

Our study shows that MS and metabolic indicators are associated with an increased risk of PCa, pointing to a novel therapeutic approach for PCa management.